日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net

在未经治疗的急性髓系白血病患者中，阿扎胞苷-维奈克拉方案首个疗程中，采用14天、21天或标准28天维奈克拉治疗的疗效相当：来自北海道白血病网的真实世界经验

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-025-01324-7
Kanaya, Minoru; Onozawa, Masahiro; Matsukawa, Toshihiro; Miyashita, Naoki; Fujii, Fumiaki; Yoshida, Shota; Nagai, Jun; Aiba, Masayuki; Hidaka, Daisuke; Hashiguchi, Junichi; Senjo, Hajime; Igarashi, Tetsuyuki; Chiba, Masahiro; Yamamoto, Satoshi; Shimizu, Taku; Ishio, Takashi; Yokoyama, Shota; Ebata, Ko; Iyama, Satoshi; Oyake, Tatsuo; Kondo, Takeshi; Teshima, Takanori
白血病
发表日期：2025
文献求助 收藏

Calcineurin inhibitor blocks tolerance by suppressing donor T cell terminal exhaustion after allogeneic hematopoietic cell transplantation

钙调磷酸酶抑制剂通过抑制同种异体造血干细胞移植后供体T细胞的终末耗竭来阻断耐受性。

期刊:Journal of Clinical Investigation
影响因子:13.6
doi:10.1172/JCI184332
Senjo, Hajime; Hashimoto, Daigo; Teshima, Takanori
发育与干细胞
T细胞
T细胞
干细胞
细胞生物学
免疫/内分泌
发表日期：2024
文献求助 收藏

Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group

对于接受免疫化疗的弥漫性大B细胞淋巴瘤患者，36个月无事件生存期是一个合适的终点指标：来自日本北部血液学研究组的真实世界证据

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2023.284841
Izumiyama, Koh; Inao, Tasuku; Goto, Hideki; Harada, Shinpei; Senjo, Hajime; Suto, Keito; Hashiguchi, Junichi; Ogasawara, Reiki; Saga, Tomoyuki; Igarashi, Tetsuyuki; Wakasa, Kentaro; Kasahara, Ikumi; Takeda, Yukari; Yamaguchi, Keisuke; Shigematsu, Akio; Takahata, Mutsumi; Fujimoto, Katsuya; Haseyama, Yoshihito; Nagashima, Takahiro; Sakai, Hajime; Kakinoki, Yasutaka; Kurosawa, Mitsutoshi; Yokota, Isao; Teshima, Takanori
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2024
文献求助 收藏

Efficacy and Safety of Single-dose Pegfilgrastim for CD34 + Cell Mobilization in Healthy Volunteers: A Phase 2 Study

单剂量培非格司亭动员健康志愿者CD34+细胞的疗效和安全性：一项II期研究

期刊:Transplantation
影响因子:5
doi:10.1097/TP.0000000000004880
Goto, Hideki; Sugita, Junichi; Hasegawa, Yuta; Hayasaka, Koji; Sunagoya, Kana; Hatase, Rie; Nishida, Mutsumi; Ichihashi, Yuki; Odera, Mitsuhiko; Senjo, Hajime; Yokoyama, Shota; Ara, Takahide; Shiratori, Souichi; Endo, Tomoyuki; Hino, Masayuki; Maeda, Yoshinobu; Sawa, Masashi; Sato, Norihiro; Teshima, Takanori
细胞生物学
CD34
CD3
发表日期：2024
文献求助 收藏

Intravenous Administration of Mesenchymal Stem Cell-Derived Exosome Alleviates Spinal Cord Injury by Regulating Neutrophil Extracellular Trap Formation through Exosomal miR-125a-3p

静脉注射间充质干细胞衍生的外泌体可通过外泌体 miR-125a-3p 调节中性粒细胞胞外陷阱形成来减轻脊髓损伤

期刊:International Journal of Molecular Sciences
影响因子:0.7
doi:10.3390/ijms25042406
Yutaka Morishima, Masahito Kawabori, Kazuyoshi Yamazaki, Soichiro Takamiya, Sho Yamaguchi, Yo Nakahara, Hajime Senjo, Daigo Hashimoto, Sakiko Masuda, Yoichiro Fujioka, Yusuke Ohba, Yuki Mizuno, Yuji Kuge, Miki Fujimura
发育与干细胞
神经
脊髓损伤
干细胞
粒细胞
发表日期：2024
文献求助 收藏

Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia

免疫性血小板减少症患者对基于mRNA的COVID-19疫苗的体液反应

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.18578
Mori, Akio; Onozawa, Masahiro; Kobayashi, Mirei; Tsukamoto, Shihori; Senjo, Hajime; Ishio, Takashi; Yokoyama, Emi; Izumiyama, Koh; Saito, Makoto; Muraki, Haruna; Morioka, Masanobu; Teshima, Takanori; Kondo, Takeshi
血小板
免疫/内分泌
发表日期：2023
文献求助 收藏

Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies

在患有髓系恶性肿瘤的患者中，第三剂基于mRNA的COVID-19疫苗的加强效应

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.6314
Mori, Akio; Onozawa, Masahiro; Kobayashi, Mirei; Tsukamoto, Shihori; Senjo, Hajime; Ishio, Takashi; Yokoyama, Emi; Kanaya, Minoru; Izumiyama, Koh; Saito, Makoto; Muraki, Haruna; Morioka, Masanobu; Teshima, Takanori; Kondo, Takeshi
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms

mRNA新冠疫苗的体液免疫反应以及成熟T细胞和NK细胞肿瘤患者接种第三剂疫苗的加强效果

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-023-05142-4
Kobayashi, Mirei; Mori, Akio; Onozawa, Masahiro; Tsukamoto, Shihori; Senjo, Hajime; Ishio, Takashi; Yokoyama, Emi; Kanaya, Minoru; Izumiyama, Koh; Saito, Makoto; Muraki, Haruna; Morioka, Masanobu; Teshima, Takanori; Kondo, Takeshi
新冠
肿瘤
T细胞
肿瘤免疫
微生物学
T细胞
细胞生物学
免疫/内分泌
发表日期：2023
文献求助 收藏

Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation

吉利替尼增强异基因造血干细胞移植后对 FLT3-ITD 突变白血病的移植物抗白血病作用

期刊:Bone Marrow Transplantation
影响因子:4.5
doi:10.1038/s41409-022-01619-4
Zixuan Zhang #, Yuta Hasegawa #, Daigo Hashimoto, Hajime Senjo, Ryo Kikuchi, Xuanzhong Chen, Kazuki Yoneda, Tomoko Sekiguchi, Tatsuya Kawase, Hirofumi Tsuzuki, Takashi Ishio, Takahide Ara, Hiroyuki Ohigashi, Masao Nakagawa, Takanori Teshima
发育与干细胞
白血病
干细胞
发表日期：2022
文献求助 收藏

High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia

CRP/白蛋白比值升高预示着不适合移植的老年新诊断急性髓系白血病患者预后不良。

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-022-12813-1
Senjo, Hajime; Onozawa, Masahiro; Hidaka, Daisuke; Yokoyama, Shota; Yamamoto, Satoshi; Tsutsumi, Yutaka; Haseyama, Yoshihito; Nagashima, Takahiro; Mori, Akio; Ota, Shuichi; Sakai, Hajime; Ishihara, Toshimichi; Miyagishima, Takuto; Kakinoki, Yasutaka; Kurosawa, Mitsutoshi; Kobayashi, Hajime; Iwasaki, Hiroshi; Hashimoto, Daigo; Kondo, Takeshi; Teshima, Takanori
白血病
CRP
发表日期：2022
文献求助 收藏